Last $20.39 USD
Change Today 0.00 / 0.00%
Volume 0.0
HLUKF On Other Exchanges
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (HLUKF) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/14 - $31.33
52 Week Low
01/7/15 - $19.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for H LUNDBECK A/S (HLUKF)

Related News

No related news articles were found.

h lundbeck a/s (HLUKF) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. H. Lundbeck A/S has strategic research collaboration with Ossianix, Inc. The company was founded in 1915 and is based in Valby, Denmark.

5,769 Employees
Last Reported Date: 11/5/14
Founded in 1915

h lundbeck a/s (HLUKF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (HLUKF) Key Developments

H. Lundbeck A/S Announces Research Partnership for Treatment of Brain Diseases Involving Seven Universities

H. Lundbeck A/S has announced a new public-private partnership involving seven universities, for the treatment of brain diseases. Lundbeck is involved in new research that will investigate a novel link that could show a relationship between the immune system and mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer's disease. This project, a public-private partnership also involving The Wellcome Trust, Cambridge University and pharmaceutical company Janssen, may be the first step towards a new and significantly improved treatment for a broad range of brain diseases. The main theory that the project will investigate is that the immune system can worsen brain diseases like depression and Alzheimer's disease. An imbalance in the immune system of the brain can drive a permanent and unhealthy neuro-inflammation - or inflammation in the brain - that can contribute to or cause brain diseases. This new project is a public-private partnership between Lundbeck and Janssen, and seven universities. The project has received a strategic award valued at approximately DKK 50m from the Wellcome Trust. The project consists of two parts. The team will begin by investigating the immune systems of people with treatment-resistant depression and Alzheimer's disease. In this phase, researchers will seek to more precisely establish the relationship between immune-related biomarkers found in blood and brain including cytokines, which are small proteins that play an important role in the regulation of the immune responses. The second part of the research program, which is reliant on the success of the first, will focus on small experimental medicine trials, using re-purposed anti-inflammatory drugs in patients who have been identified according to their specific immunological profile or 'phenotype'.

H. Lundbeck A/S Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 08:30 AM

H. Lundbeck A/S Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Hakan Bjorklund, Interim CEO & Chairman of the Board.

H. Lundbeck A/S Presents at SEB Nordic Seminar, Jan-08-2015 04:30 PM

H. Lundbeck A/S Presents at SEB Nordic Seminar, Jan-08-2015 04:30 PM. Venue: Hilton Copenhagen Airport Hotel, Copenhagen, Denmark.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUKF:US $20.39 USD 0.00

HLUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $18.27 USD -0.59
Emergent Biosolutions Inc $28.03 USD -0.77
Lupin Ltd 1,585 INR +30.75
Nektar Therapeutics $14.64 USD -0.42
Salix Pharmaceuticals Ltd $134.67 USD -0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation HLUKF Industry Range
Price/Earnings 46.8x
Price/Sales 1.7x
Price/Book 1.7x
Price/Cash Flow 46.8x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at